



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2024 #1

January 5, 2024

INSIDE:

NBDM Recognized by Blood Community	3
WORD IN WASHINGTON	3
RESEARCH IN BRIEF	3
Register for the ABC WELC Webinar Featuring Kristin Hadeed	5
Program Available for 2024 ABC Annual Meeting.....	5
Registration Is Open for 2024 ADRP Annual Conference.....	5
MEMBER NEWS.....	6
GLOBAL NEWS	6
COMPANY NEWS	7
CALENDAR.....	9
POSITIONS.....	10

Blood Community Responds to ACBTSA Recommendations

America's Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross (ARC) submitted [public comments](#) to the U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) in response to [additional recommendations related to sustainability](#) of the U.S. blood supply during national emergencies. The blood community expressed their support for recommendations that government resources are made available to blood centers during national and regional emergencies.

Additionally, the three organizations endorsed the recommendation that the Zika payment model be used during long-term emergencies to support the collection and manufacture of blood components to allow for a minimum 10 percent increase over baseline usage during emergencies when surge capacity is required. However, the blood community also, “encourage[d] expansion of the model to ensure blood establishments are not collecting blood at risk and are receiving necessary financial support through cost recovery funding, similar to the collection and distribution of COVID-19 convalescent plasma (CCP); and establish[ing] funding for local public awareness about the need for blood donors.”

The comments from the blood community emphasized that the, “best use of any future federal funding for public awareness for blood donation is best directed locally.” Specifically, ABC, AABB, and ARC explained that it is, “essential that the U.S. government invest in local funding for blood establishments to use in increasing awareness of blood donation, especially among diverse, young, and newly eligible individuals.”

Other recommendations proposed by the blood community included:

- “the HHS Office of Infectious Disease and HIV/AIDS Policy (OIDP) create a publicly available action plan that includes specific activities to safeguard the availability of blood; and indicates how the agency intends to implement coordination and collaboration with other federal entities, including the U.S. Food and Drug Administration (FDA);”
- specifically identifying HHS funding agencies that companies providing “critical supplies for blood manufacturing and storage shall work [with] to develop and enact contingency plans to stabilize the blood supply chain;”

(continued on page 2)

Blood Community Responds to ACBTSA Recommendations (continued from page 1)

- requesting that the “ACBTSA also recommend that the Assistant Secretary of Health recommend that the Administration for Strategic Preparedness and Response (ASPR) elucidate its role in stabilizing the blood supply chain and revise its policies pertaining to Medical Countermeasures (MCMs) to ensure the availability of essential items, including but not limited to, blood bags, saline, reagents, pipettes and other critical components necessary for maintaining a secure and adequate blood supply;”
- identify the specific HHS funding organizations who can “offer grant or contract funding that enables the development of novel means for extending the outdate of perishable materials in the stockpile; [and] specify which agencies within HHS are responsible for advancing strategies to extend the shelf life of perishable materials;”
- the blood community also recommended, “that HHS, including the FDA, work to convene a multi-organizational working group, including government agencies and national experts from leading blood associations and organizations, to identify potential opportunities to pre-establish additional regulatory flexibility that could be granted in case of short- or long-term surge capacity needs to extend the U.S. blood supply without impacting the safety, purity, or potency of blood donation. This analysis shall include an assessment of risks and burden[s] associated with the different temporary options;” and include actionable goals and anticipated outcomes.

ABC, AABB, and ARC concluded the comments with recommendations regarding surge capacity:

- “establishment of a baseline inventory of blood;
- modeling of unprecedented emergency scenarios; and
- funding for a sustained increase in blood inventories.”

The ACBTSA will hold its next [meeting](#) on January 11th to discuss and vote on recommendations. ABC previously submitted comments in response to recommendations from the ACBTSA in [November](#) and [June](#) of 2023.

(Source: ACBTSA [Joint Comments](#), 12/22/23) 



The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2024 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$420

Send subscription queries to memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

NBDM Recognized by Blood Community

America's Blood Centers, the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross issued a joint [news release](#) encouraging eligible individuals to schedule an appointment to donate blood during National Blood Donor Month (NBDM). The news release expressed the blood community's appreciation for those who donated over the past year, while also highlighting and welcoming newly eligible donors following the U.S. Food and Drug Administration's shift to individual donor assessments.

(Source: NBDM Joint [News Release](#), 12/20/23) ◆

WORD IN WASHINGTON

Anne Eder, MD, PhD has been named director of the Office of Blood Research and Review (OBRR) in the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). According to the announcement, "Dr. Eder most recently served as the acting Office Director of OBRR and has been the Deputy Office Director of OBRR since 2019. She joined FDA in 2016 as Associate Deputy Division Director, Division of Emerging and Transfusion Transmitted Diseases (DETTD) in OBRR. Dr. Eder received her MD and PhD from the University of Iowa and completed a Clinical Pathology Residency followed by a Blood Banking/Transfusion Medicine Fellowship at the Hospital of the University of Pennsylvania. After working for several years on staff at Children's Hospital of Philadelphia, she held senior positions at the American Red Cross and the National Institutes of Health in Blood Banking/Transfusion Medicine prior to coming to FDA. She brings a wealth of experience to the Office Director position."

(Source: FDA Announcement, 1/4/24)

The Federal Trade Commission (FTC) and Justice Department have published [updated merger guidelines](#). According to the FTC news release, the [2023 Merger Guidelines](#) "describe factors and frameworks the agencies utilize when reviewing mergers and acquisitions. The 2023 Merger Guidelines are the culmination of a nearly two-year process of public engagement and reflect modern market realities, advances in economics and law, and the lived experiences of a diverse array of market participants."

(Source: FTC [News Release](#), 12/18/23) ◆

RESEARCH IN BRIEF

Optimizing Platelet Transfusion Through Deep Learning. A [study](#) in *Blood*, "aimed to create a personalized support system for platelet concentrates (PC) demand management by designing a deep learning (DL) model that computes a risk score." The authors explained that, "[t]he risk score, a decimal between 0 and 1, expresses the likelihood a patient will need a platelet transfusion in the next 24 hours." A higher score indicates a greater likelihood that a transfusion will be needed." They noted that the retrospective study used, "an expanding window approach, [and] created a training and live-prediction pipeline with a 30-day input and 24-hour forecast...As a search strategy, Bayesian optimization was chosen, and the goal was to maximize the best area under the precision-recall curve (AUC-PR) score." The study group included, "34,809 individuals hospitalized between 2017 and 2022...When analyzed by clinical departments, 57 percent of PCs were applied in the hematology-oncology department, 19 percent in the cardiothoracic surgery department, and 24 percent in other departments...On the validation set, the multispecialty model achieved a mean performance of 0.72 AUC-PR in 400 trained models, with the best model achieving a score of 0.77 AUC-PR." The researchers found that, "[t]he cardiothoracic model had a mean performance of 0.43 in 700 runs, with the best model achieving a score of 0.45 AUC-PR. The hematology-oncology model had a mean

(continued on page 4)

RESEARCH IN BRIEF (continued from page 3)

performance of 0.81 in 700 runs, with the best model achieving a score of 0.84 AUC-PR... The ideal threshold for the cardiothoracic model was identified as 0.39. For the multispecialty models, it was identified as 0.47, and for the hematology-oncology model, it was 0.41. A risk score exceeding these thresholds indicates the patient has a high likelihood of needing a platelet transfusion.” The authors also noted that, “[i]nterestingly, the platelet count was not among the most relevant features contributing to the model’s prediction. The most relevant sequential feature was the weekday. This reflects the predominating impact of different operational practices between weekends and weekdays and operating room schedules.” They concluded that, “this is the first DL-based platelet transfusion predictor enabling individualized 24-hour risk assessments at high AUC-PR... Implemented as a decision-support system for platelet monitoring, DL forecasts might improve patient care by means of earlier detection of platelet demand and prevention of critical transfusion shortages.”

Citation: Engelke, M., Schmidt, C.S., Baldini, G., *et al.* [Optimizing platelet transfusion through a personalized deep learning risk assessment system for demand management](#). *Blood*. 2023

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

Upcoming ABC Webinars & Virtual Events – Don’t Miss Out!

- **America’s Blood Centers (ABC) Quality Assurance (QA) Education Webinar: Back to Basics – Part 2** – Jan. 16th. More information available to ABC Members including a link to registration in [MCN 23-103](#).
- **ABC & ADRP, the Association for Blood Donor Professionals Webinar: Unlocking the Power of Personal Stories** – Jan. 17th. [Registration](#) is open. More information available [here](#).
- **ABC WELC Webinar: Harness Your Authenticity** – Jan. 18th. More information available to ABC Members, including a link to registration in [MCN 23-102](#).



ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Register for the ABC WELC Webinar Featuring Kristin Hadeed

America's Blood Centers (ABC) [Women's Executive Leadership Community](#) (WELC) will host its next [webinar](#), titled "Harness Your Authenticity," on January 18th at 2 p.m. EST. This virtual event is designed to have participants:

- challenge their mindset;
- find their sweet spot;
- own their growth;
- have courageous conversations; and
- just be human.

This webinar will provide attendees with tools and information to open yourself to new ideas, be fully present in your work, and establish meaningful connections and results. A workbook of exercises related to the webinar is available to attendees.

Ms. Hadeed is a "nationally featured leadership speaker and author. She believes that authentic, human leadership can change the world. Her work has been featured in news outlets including PBS, FOX, Inc., NBC, *TIME*, and *Forbes*. Ms. Hadeed's book, 'Permission To Screw Up,' has sold more than 50,000 copies worldwide. Her first TED Talk has more than three million views on YouTube."

(Source: [MCN 23-102](#), 12/14/23)

Program Available for 2024 ABC Annual Meeting

[Registration](#) is open for the ABC [2024 Annual Meeting](#) and the [program](#) is available. The meeting will take place March 4th-6th in Arlington, Va. at the Ritz-Carlton in Pentagon City and features several exciting changes, including expanded content offerings and a new format. With a focus on advocacy, leadership, operations, and science and medicine, the program will feature a mix of general and breakout sessions, external speakers and blood center-led case studies, committee and council meetings, networking events, and more. *Awards of Excellence* (AoE) winners will be [recognized](#) throughout the Annual Meeting and at a reception on Capitol Hill, where we can celebrate their achievements with fellow meeting attendees, members of Congress and their staff, our federal agency partners, Blood Advocacy Week partners, and more. Secure your [room](#) today to take advantage of the group rate. The deadline to book a room is February 16th. [Sponsorship](#) opportunities are also available. [Contact us](#) with any questions.

Registration Is Open for 2024 ADRP Annual Conference

[Register](#) today for the [2024 ADRP Annual Conference](#)! Join more than 400 blood center professionals in St. Louis, Mo. May 14th-16th at The St. Louis Union Station Hotel. Take advantage of the member-only early bird discount rate by registering by January 31st. This year's conference will feature keynotes [Jason Kotecki](#), an expert at helping people "Escape Adulthood" in order to beat burnout and become more innovative and creative by breaking rules that don't exist, and [Candy Whirley](#), a recognized motivational

(continued on page 6)

INSIDE ABC (Continued from page 5)

speaker, leadership, and team building expert. The 2024 ADRP Annual Conference is your opportunity to gain insights into industry trends, exchange ideas, and share information with your peers, while taking advantage of networking opportunities. Attendees will be able to participate in pre-conference workshops, educational sessions, roundtables, and have access to an expansive exhibit hall. [Learn more](#) about available exhibitor and sponsorship opportunities. Remember to [book](#) your hotel room by April 19th for the discounted rate. Please contact [us](#) with questions. 💧

MEMBER NEWS



LifeSouth Community Blood Centers [held](#) a ribbon cutting ceremony for their new operations building and donor center in Dothan, Ala. “After serving the community’s hospitals for over 20 years, we are proud of the tremendous team effort that went into our newest standalone building,” said Kim Kinsell, JD, president and chief executive officer of LifeSouth Community Blood Centers, in a news release. “The structure is impressive with clean, modern spaces and reflects our ongoing commitment to the southeastern Alabama region, our team and our blood donors.” The ceremony included, “representatives from local hospitals, the Dothan Area Chamber of Commerce, community leaders, blood donors, and the design and construction teams” of the new 6,450 square foot facility.

(Source: LifeSouth Community Blood Centers [News Release](#), 12/28/23)

BioLinked, a blood center network including several members of America’s Blood Centers and founded by **Our Blood Institute**, is [partnering](#) with Scripps Research as part of the National Institutes of Health’s “All of Us” research program. According to KAMR-TV, the program will, “focu[s] on accelerating research and improving health equality through the continued effort to engage one million diverse blood center partners and participants throughout the U.S. BioLinked Executive Director Brad Bryan, PhD, MBA added, “to truly advance research, we must ensure that our studies reflect the diversity of the populations we aim to serve. Thus, no one is left behind in the pursuit of better healthcare. I am grateful and exhilarated to support the All of Us Research Project’s noble initiative to expand the representation of underrepresented groups in biomedical research.”

(Source: KAMR-TV, “[BioLinked partners with Scripps Research to progress research program that expands blood center network](#), 12/5/23) 💧

GLOBAL NEWS

The World Health Organization (WHO) recently published a [document](#) titled “**Guidance to identify barriers in blood services using the [blood system self-assessment \(BSS\) Tool](#).**” The agency described the document as a resource that aims to “help stakeholders assess their blood systems through a stepwise questionnaire that identifies its strengths and challenges. Ultimately, the objective of this questionnaire and associated resources is to help countries understand how to move towards a well-functioning blood system.” Both the guidance and BSS Tool are currently available in English as the WHO works to develop translated versions in Spanish, French, Arabic, Russian, and Chinese in 2024. ADRP Past President Gavin Evans took part in the WHO Working Group that helped create the BSS Tool.

(Sources: WHO [Guidance](#), 11/23/23; WHO [BSS Tool](#), 11/23/23)

(continued on page 7)

GLOBAL NEWS (continued from page 6)

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) announced that it has [recommended](#) the first gene editing therapy to treat beta thalassemia and severe sickle cell disease for approval. According to the announcement, “Casgevy is recommended for a conditional marketing authori[z]ation, one of the European Union’s [EU] regulatory mechanisms to facilitate early access to medicines that fulfill an unmet medical need. This type of approval allows the Agency to recommend a medicine for marketing authori[z]ation with less complete data than normally expected, if the benefit of a medicine’s immediate availability to patients outweighs the risk inherent in the fact that not all the data are yet available. In order to confirm the efficacy and safety of Casgevy, the company will have to submit the final results obtained from the currently ongoing pivotal trials by August 2026, as well as results from the ongoing long-term follow-up study and other studies that will be conducted with the product. Patients treated with Casgevy will be followed up for 15 years, to monitor the long-term efficacy and safety of this gene therapy.” The U.S. Food and Drug Administration [approved](#) the treatment in December 2023.

(Source: EMA [Announcement](#), 12/15/23) 💧

COMPANY NEWS

GenCure, a subsidiary of BioBridge Global, has [partnered](#) with the University of Texas San Antonio (UTSA). Through the collaboration, “GenCure will provide starting materials for UTSA researchers to facilitate the isolation and subsequent reprogramming of adult stem cells to generate induced Pluripotent Stem Cells (iPSCs),” according to a company news release. As part of the partnership, UTSA will also provide, “testing services for materials manufactured by GenCure’s process development and cGMP facilities.”

(Source: GenCure [News Release](#), 12/20/23)

Editas Medicine, Inc. has [announced](#) new safety and efficacy findings from clinical trials of its investigational gene editing treatment, reni-cel, for individuals with severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The investigational treatment was, “well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant by all patients in the two trials (n=17). Since treatment with reni-cel, all RUBY [trial] patients are free of vaso-occlusive events (VOEs) (n=11). All RUBY patients with ≥5 months follow-up have maintained a normal hemoglobin level and a fetal hemoglobin level of >40%. All EdiTHAL [trial] patients had early and robust increase of total hemoglobin, above the transfusion independence threshold of 9 g/dl (n=6).” According to the news release, the investigational treatment, “consists of patient-derived CD34⁺ hematopoietic stem and progenitor cells edited at the gamma globin gene (HBG1 and HBG2) promoters, where naturally occurring fetal hemoglobin (HbF) inducing mutations reside, by As-Cas12a, a novel, proprietary, highly efficient, and specific gene editing nuclease. Red blood cells derived from reni-cel CD34⁺ cells demonstrate a sustained increase in fetal hemoglobin production, which has the potential to provide a one-time, durable treatment benefit for people living with severe SCD and TDT.”

(Source: Editas Medicine, Inc. [News Release](#), 12/11/23)

Pfizer Inc. recently [shared](#) data from a phase III clinical trial of its investigational monoclonal antibody treatment for individuals with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). According to a news release, 116 individuals with hemophilia received the investigational monoclonal antibody, marstacimab, weekly, “during a 12-month

(continued on page 8)

COMPANY NEWS (continued from page 7)

active treatment period (ATP) versus a routine prophylaxis (RP) and on-demand (OD) intravenous regimen with FVIII or FIX, administered as part of usual care in a six-month observational period.” The data showed that, “[c]ompared to RP, treatment with marstacimab resulted in a 35.2% mean reduction (95% CI: 5.6-55.6; $p=0.0376$) in annualized bleeding rate (ABR) over 12 months (mean of 7.85 [5.09-10.61] to 5.08 [3.40-6.77]). Marstacimab significantly reduced ABR by 91.6% (95% CI: 88.1-94.1; $p<0.0001$) compared to OD over 12 months (mean of 38.00 [31.03-46.54] to 3.18 [2.09-4.85]). The mean ABR reductions observed with marstacimab were consistent across hemophilia A and B and age groups for OD and were generally consistent across hemophilia A and B and age groups for RP, with all point estimates for a difference <2.5 (non-inferiority margin for the ABR of treated bleeds). Following 12 months in the ATP, patients had the option to continue receiving marstacimab in the long-term extension (LTE) study. In the LTE, a consistent reduction in ABR compared to OD (mean ABR of 3.86 [2.02-7.37]) and further numerical reduction compared to RP (mean ABR of 2.27 [1.40-3.67]) were observed after up to an additional 16 months of follow-up ($n=87$). In the OD group, superiority ($p<0.0001$) of marstacimab was demonstrated across all bleeding-related secondary endpoints - spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds. In the RP group, marstacimab demonstrated non-inferiority to these secondary efficacy endpoints. Health-related quality of life parameters showed non-significant improvements vs OD therapy and non-inferiority versus RP therapy. The safety profile for marstacimab was consistent with Phase I/II results and treatment was generally well-tolerated. No deaths were reported and there have been no thromboembolic events or events of consumptive coagulopathy recorded in hemophilia patients in clinical trials investigating marstacimab.”

(Source: Pfizer, Inc. [News Release](#), 12/9/23) 💧

**NEW on CollABOrate****COLLABORATE**

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC [CollABOrate](#) Online Member Community include:

- [Hgb Results](#) (COLLECTIONS & DONOR SERVICES)
- [Venipuncture Loss Rates](#) (COLLECTIONS & DONOR SERVICES)
- [Cold Storage Platelets](#) (TECHNICAL DIRECTORS)

ABC members are encouraged to [login](#) and join the conversations today!

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2024

Jan. 11. **U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) (Virtual)**. More information available [here](#).

Jan. 16. **America's Blood Centers (ABC) Quality Assurance (QA) Education Webinar: "Back to Basics – Part 2" (Virtual)**. More information available to ABC Members including a link to registration in [MCN 23-103](#).

Jan. 17. **ABC & ADRP, the Association for Blood Donor Professionals Webinar: "Unlocking the Power of Personal Stories" (Virtual)**. [Registration](#) is open. More information available [here](#).

Jan. 18. **ABC Women's Executive Leadership Community Webinar: "Harness Your Authenticity" (Virtual)**. More information available to ABC Members including a link to registration in [MCN 23-102](#).

Feb.7-8. **International Plasma and Fractionation Association & EBA Symposium on Plasma Collection and Supply. Leiden, Netherlands**. [Registration](#) is open. More information available [here](#).

Mar. 4-6. **ABC Annual Meeting, Arlington, Va**. [Registration](#) is open. More information available [here](#).

April 11-12. **International Haemovigilance Network Symposium. Athens, Greece**. [Registration](#) is open. More information available [here](#).

April 12-13. **BEST Meeting. Amsterdam, Netherlands**. More information coming soon.

April 17-18. **ABC Quality and Technical Workshop, St. Louis, Mo**. [Registration](#) is open. More information available [here](#).

May 14-16. **2024 ADRP Annual Conference, St. Louis, Mo**. [Registration](#) is open. More information available [here](#).

May 15-16. **International Plasma and Fractionation Association/Paul-Ehrlich Institut[e] 30th International Workshop on Surveillance and Screening of Blood-borne Pathogens, Aarhus, Denmark**. [Registration](#) is open. More information available [here](#).

June 23-27. **38th International Society of Blood Transfusion (ISBT) Congress. Barcelona, Spain**. [Registration](#) is open. More information available [here](#).

Sept. 4-6. **American Society for Clinical Pathology (ASCP), Chicago, Ill**. More information coming soon.

Sept. 30- Oct. 3. **American Association of Tissue Banks (AATB), Denver, Colo**. More information coming soon.

Oct. 19-22. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, Houston, Texas**. More information coming soon. 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Account Manager, Blood Processing Solutions (Macopharma USA). Macopharma is a worldwide innovative Health Care Company specializing in Transfusion Medicine and Cellular Therapy. For more than 45 years, Macopharma has achieved continuous growth and success in these fields. In all our activities, we focus on the improvement of human health outcomes. This position is responsible for developing and maintaining relationships that lead to sales of blood filters, equipment, and related products. Travel required three to four nights per week. Must live near a major airport. Knowledge of blood transfusion and blood center operations essential. Key Responsibilities: Develops and implements strategies to maintain and/or expand sales within an assigned territory. Prepares a plan for each customer to identify needs and how Macopharma Blood Product Solutions can support the customer's success. Contacts customers regularly to maintain account relationship, advise of new product and service offerings, and obtain feedback on products. Provides post implementation support to assigned customers. Participates in trade shows. Contributes to business forecasting providing accurate trends and future client needs. Profile: Bachelor's degree. Five (5) years' experience in blood banking/medical device/cellular therapy. Three (3) years proven documented sales success. O365 proficient. Qualified applicants may request job description and send resume to resumes@macopharmausa.com.

Hospital Services and Manufacturing Manager. The Blood Bank of Alaska (BBA) is looking for a Hospital Services and Manufacturing Manager. The Hospital Services and Manufacturing Manager is responsible for ensuring there is an adequate blood supply to meet customer needs. Overseeing import of needed blood components and actively exporting excess blood products, as needed. Ensuring blood products are stored and monitored in compliance with FDA, AABB and Blood Bank of Alaska's (BBA) regulatory requirements. Ensuring adherence and compliance to BBA's Standard Operating Procedures (SOPs). Overseeing the processing, packing, and shipping of blood products. Overseeing the quality control program for storage of blood products. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status or any other legally protected status. Interested candidates please apply online at <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

Director of Hospital Services and Manufacturing. The Blood Bank of Alaska is looking for a Director of Hospital Services and Manufacturing. The Director of Hospital

Services and Manufacturing is responsible for ensuring alignment of teams with organizational goals and compliance with regulatory guidelines. Participates as a member of the blood bank's management team in planning, program formulation and decision making with reference to the role, functions and technical support of the manufacturing and distribution of blood products. Fosters and enhances customer hospital relations. This person ensures a dedicated focus on the production and distribution of quality products in a timely manner while providing the highest level of customer service. Also ensures all procedures are followed and promotes a positive work environment. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status or any other legally protected status. Interested candidates please apply online at <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

Laboratory Services Manager. The Blood Bank of Alaska is looking for a Laboratory Services Manager. Under the general direction of the Director of Laboratory Services, this person is responsible for oversight of daily laboratory operations ensuring that laboratory product QC and donor test results meet CLIA, AABB and FDA compliance standards/regulations for the manufacture of blood products. The Laboratory Services Manager is also responsible for oversight of laboratory personnel. This position is full-time exempt. The Blood Bank of Alaska offers competitive wages and an exceptional benefits plan. We offer medical, dental, vision, life, and short/long term disability programs to qualified employees. Educational assistance, paid annual leave and holidays and a 401 (k) program are also available. The Blood Bank is an equal opportunity employer. Qualified applicants are considered for employment without regard to race, color, religion, national origin, age, disability, marital/veteran status or any other legally protected status. Interested candidates please apply online at <https://bloodbankofalaska.apscareerportal.com>. A complete job description can be found there as well.

Implementation Specialist. Blood Bank Computer Systems (BBCS) is hiring a remote Implementation Specialist. Reporting to the Client Services Manager, this position will be responsible for establishing, maintaining and managing client implementation work plans, assisting with the installation/upgrade of BBCS applications at client facilities, assisting the client in meeting the projected Go Live dates, new client management training,

(continued on page 11)

POSITIONS (continued from page 10)

on-site consultations and training. Requirements: Bachelor's degree, three (3) plus years of successful project management/implementation experience, tradeshow participation, product and industry knowledge, experience with healthcare and/or IT implementation. To view the full job description and apply visit our BBCS careers website at: <https://www.bbcinc.com/about-bbcs-careers/>

Manager of Donor Resources. The Blood Connection is seeking a Manager of Donor Resources for our operations based out of Piedmont, SC. This position will be responsible for monitoring progress to goal proactively, and effectively coaching and managing their team to success. The ideal candidate for this position possesses strong leadership and organizational skills with a proven ability to meet organizational goals. We offer a generous benefits package including a substantial 401k, 30 days PTO potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help create a positive change in your community. *Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Donor Resources Application](#)

Manager of Donor Services. The Blood Connection is seeking a Manager of Donor Services for our operations based out of Rock Hill, SC. This position will oversee donor collection operations within their assigned divisional territory. This position provides leadership and discipline to direct reports, interviews, and hires staff, and ensures staff are appropriately trained. We offer a generous benefits package including a substantial 401k, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help create a positive change in your community. *Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Donor Services Application](#)

Director of Quality Assurance. Sheppard Community Blood Center in Augusta, Georgia, is looking for an ambitious leader to modernize its approach to product safety and compliance. Sheppard serves several communities in rapidly growing communities in Georgia and South Carolina. The ideal candidate will have at least six years of experience in blood banking, quality assurance, or compliance. Responsibilities include serving as the subject matter expert in regulatory compliance; working with operational leaders to help advance business goals; and overseeing the review and implementation of SOPs, validations, maintenance, reporting, and other related processes. The leader selected for this role must see themselves as an integral member of the leadership team and dedicated to achieving the organization's strategic plan and long-term goals. Those interested can apply at sheppardblood.org.

Vice President of Medical Services & Chief Medical Officer (VP/CMO) - Position starting July 1, 2024. The Vice President of Medical Services & Chief Medical Officer (VP/CMO) is responsible for the medical and technical leadership of Carter BloodCare (CBC) operations. This individual also shares administrative duties with the other vice presidents under the Chief Executive Officer. This is the administrative head of the Medical Services department, including directly overseeing five (5) Medical Directors. The Department of Clinical Apheresis, immunohematology reference lab, three transfusion services at off-site hospitals, the Cellular Therapy processing lab, Donor Notification, and Procedure Development all report up to the VP/CMO. This individual will serve as the CLIA director for the main CBC laboratories. VP/CMO will help develop new business opportunities for the abovementioned departments, as well as promote relations with local customers and participate in resident/fellow teaching with the local medical schools. **Required Education:** M.D., D.O., or equivalent degree; active Texas medical license; and Board eligible or board certified in primary field of training. **Preferred Education:** Completed pathology or internal medicine/hematology residency training. Board eligible or board-certified in Blood Banking and Transfusion Medicine by the American Board of Pathology. MBA or other business degree or certificate work. Carter BloodCare is an EEO/Affirmative Action employer. Apply at www.carterbloodcare.org/careers.

Manager of Donor Resources. The Blood Connection is expanding our operations into Virginia! We are one of the fastest growing blood centers in the country and we are seeking a Manager of Donor Resources who will provide management and oversight of the Donor Resources department as we expand into this new territory. The ideal candidate for this position possesses strong leadership and organizational skills with a proven ability to meet organizational goals. We offer a generous benefits package including a substantial 401k, 30 days PTO, potential company bonuses, cell phone stipend, and tuition reimbursement. Join our team and help create a positive change in your community. *This role is based in Roanoke, VA. Prospective candidates may be eligible for relocation assistance.* How to apply: [Manager of Donor Resources Application](#) 💧